Clinical Trial Update: GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update outlines a Phase 1/Phase 2 study of GP350 CAR-T for relapse/refractory Epstein-Barr virus-associated lymphoid neoplasms, currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus-associated Lymphoid Neoplasms

Drugs mentioned

• GP350 CAR-T

Snippet

Sponsor: Zhimin Zhai | Conditions: EBV Associated Lymphoid Neoplasms | Phase 1, Phase 2 | Status: RECRUITING